Literature DB >> 34200360

RAD51D Aberrant Splicing in Breast Cancer: Identification of Splicing Regulatory Elements and Minigene-Based Evaluation of 53 DNA Variants.

Elena Bueno-Martínez1, Lara Sanoguera-Miralles1, Alberto Valenzuela-Palomo1, Víctor Lorca2, Alicia Gómez-Sanz2, Sara Carvalho3, Jamie Allen3, Mar Infante4, Pedro Pérez-Segura2, Conxi Lázaro5, Douglas F Easton3, Peter Devilee6, Maaike P G Vreeswijk6, Miguel de la Hoya2, Eladio A Velasco1.   

Abstract

RAD51D loss-of-function variants increase lifetime risk of breast and ovarian cancer. Splicing disruption is a frequent pathogenic mechanism associated with variants in susceptibility genes. Herein, we have assessed the splicing and clinical impact of splice-site and exonic splicing enhancer (ESE) variants identified through the study of ~113,000 women of the BRIDGES cohort. A RAD51D minigene with exons 2-9 was constructed in splicing vector pSAD. Eleven BRIDGES splice-site variants (selected by MaxEntScan) were introduced into the minigene by site-directed mutagenesis and tested in MCF-7 cells. The 11 variants disrupted splicing, collectively generating 25 different aberrant transcripts. All variants but one produced negligible levels (<3.4%) of the full-length (FL) transcript. In addition, ESE elements of the alternative exon 3 were mapped by testing four overlapping exonic microdeletions (≥30-bp), revealing an ESE-rich interval (c.202_235del) with critical sequences for exon 3 recognition that might have been affected by germline variants. Next, 26 BRIDGES variants and 16 artificial exon 3 single-nucleotide substitutions were also assayed. Thirty variants impaired splicing with variable amounts (0-65.1%) of the FL transcript, although only c.202G>A demonstrated a complete aberrant splicing pattern without the FL transcript. On the other hand, c.214T>C increased efficiency of exon 3 recognition, so only the FL transcript was detected (100%). In conclusion, 41 RAD51D spliceogenic variants (28 of which were from the BRIDGES cohort) were identified by minigene assays. We show that minigene-based mapping of ESEs is a powerful approach for identifying ESE hotspots and ESE-disrupting variants. Finally, we have classified nine variants as likely pathogenic according to ACMG/AMP-based guidelines, highlighting the complex relationship between splicing alterations and variant interpretation.

Entities:  

Keywords:  ESE; ESS; RAD51D; VUS; aberrant splicing; breast cancer; clinical interpretation; minigene; ovarian cancer; susceptibility genes

Year:  2021        PMID: 34200360     DOI: 10.3390/cancers13112845

Source DB:  PubMed          Journal:  Cancers (Basel)        ISSN: 2072-6694            Impact factor:   6.639


  4 in total

1.  Minigene Splicing Assays Identify 20 Spliceogenic Variants of the Breast/Ovarian Cancer Susceptibility Gene RAD51C.

Authors:  Lara Sanoguera-Miralles; Elena Bueno-Martínez; Alberto Valenzuela-Palomo; Ada Esteban-Sánchez; Inés Llinares-Burguet; Pedro Pérez-Segura; Alicia García-Álvarez; Miguel de la Hoya; Eladio A Velasco-Sampedro
Journal:  Cancers (Basel)       Date:  2022-06-15       Impact factor: 6.575

2.  Cytoprotective Activity of Polyamines Is Associated with the Alternative Splicing of RAD51A Pre-mRNA in Normal Human CD4+ T Lymphocytes.

Authors:  Yulia A Gladilina; Lylia Bey; Abdullah Hilal; Ekaterina V Neborak; Varvara G Blinova; Dmitry D Zhdanov
Journal:  Int J Mol Sci       Date:  2022-02-07       Impact factor: 5.923

3.  Splicing predictions, minigene analyses, and ACMG-AMP clinical classification of 42 germline PALB2 splice-site variants.

Authors:  Alberto Valenzuela-Palomo; Elena Bueno-Martínez; Lara Sanoguera-Miralles; Víctor Lorca; Eugenia Fraile-Bethencourt; Ada Esteban-Sánchez; Susana Gómez-Barrero; Sara Carvalho; Jamie Allen; Alicia García-Álvarez; Pedro Pérez-Segura; Leila Dorling; Douglas F Easton; Peter Devilee; Maaike Pg Vreeswijk; Miguel de la Hoya; Eladio A Velasco
Journal:  J Pathol       Date:  2021-12-28       Impact factor: 9.883

4.  Minigene-based splicing analysis and ACMG/AMP-based tentative classification of 56 ATM variants.

Authors:  Elena Bueno-Martínez; Lara Sanoguera-Miralles; Alberto Valenzuela-Palomo; Ada Esteban-Sánchez; Víctor Lorca; Inés Llinares-Burguet; Jamie Allen; Alicia García-Álvarez; Pedro Pérez-Segura; Mercedes Durán; Douglas F Easton; Peter Devilee; Maaike Pg Vreeswijk; Miguel de la Hoya; Eladio A Velasco-Sampedro
Journal:  J Pathol       Date:  2022-07-15       Impact factor: 9.883

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.